Scopus Eşleşmesi Bulundu
14
Atıf
45
Cilt
3371-3374
Sayfa
Scopus Yazarları: Leylagul Kaynar, Gokmen Zararsiz, Süleyman Baldane, T. Ozenmis, M. Keklik, Bulent Eser, Fatih Kurnaz, H. Sivgin, Mustafa Cetin, Serdar Sivgin, Ali Ünal
Özet
Objective Serum albumin level is considered to be a marker reflecting the nutritional status in both healthy subjects and patients with malignancies. In this study we sought to investigate the association between pretransplantation serum albumin levels and prognosis among patients with leukemia who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT). Methods We retrospectively analyzed the data of 102 patients who underwent alloHSCT from 2004 to 2010. Pretransplant serum albumin, D-dimer, creatinine, and fibrinogen levels drawn within 10 days before transplantation were obtained from patient files. All parameters were divided into 2 groups: normal levels (group 1) versus abnormal levels (group 2). Our normal range of serum albumin is 3.2-5.2 g/dL; patients with pretransplantation albumin level ≥3.2 g/dL were included in group 1 versus group 2 with <3.2 g/dL. Results The patients included 42 (41.1%) female and 60 (58.9%) male patients. The diagnoses were acute myeloblastic leukemia in 65 (63.7%) and acute lymphoblastic leukemia in 37 (36.3%). The median age was 26.0 years (range, 13-57). Univariate and multivariate analysis showed that patients with serum albumin levels <3.2 g/dL experienced significantly lower overall survival (OS) compared with ≥3.2 g/dL (hazard ratio [HR] 2.32 [range, 1.23-4.54] and HR 2.70 [range 1.38-5.26], respectively; P =.009). The median (range) OS in group 2 was 230.0 (184.0-544.0) days versus 570.5 (249.5-1,101.0) days in group 1 (P =.007). For disease free survival (DFS) evaluation, univariate and multivariate analysis showed that patients with serum albumin levels <3.2 g/dL had significantly lower values compared with patients with serum albumin ≥3.2 g/dL. (HR 2.17 [range 0.98-4.76] and HR 2.85 [range, 1.25-6.66], respectively; P =.046). The median (range) DFS in group 2 was 184.0 (61.0-524.0) days versus 445.0 (199.0-917.5) days in group 1 (P =.045). Among the patient characteristics the presence of infection was a significant independent variable for worse OS (HR 2.12 [range, 0.98-4.36], P =.036). The other parameters - age, sex, donor status, time to transplant interval, conditioning regimens, HLA status, and number of total infused CD34+ cells - showed no significant effect on OS and DFS (P =.05). Conclusions Pretransplantation decreased serum albumin levels were associated with poor survival in patients with leukemia who underwent alloHSCT. © 2013 by Elsevier Inc. All rights reserved.
Scimago Dergi Bilgisi
Otomatik ISSN Eşleştirmesi
2013 yılı verileri
Transplantation Proceedings
Q2
SJR Quartile
0,479
SJR Skoru
93
H-Index
Kategoriler: Surgery (Q2) · Transplantation (Q2)
Alanlar: Medicine
Ülke: United States
· Elsevier Inc.
Bu bilgiler makale yılına göre Scimago veritabanından ISSN eşleştirmesiyle otomatik getirilmektedir.
Dergi sıralama verileri Scimago'nun ilgili yılı baz alınmaktadır.
Makale Bilgileri
Dergi
Transplantation Proceedings
ISSN
00411345
Yıl
2013
/ 11. ay
Cilt / Sayı
45
/ 9
Sayfalar
3371 – 3374
Makale Türü
Özgün Makale
Hakemlik
Hakemli
Endeks
SCI-Expanded
Yayın Dili
İngilizce
Kapsam
Uluslararası
Toplam Yazar
11 kişi
Erişim Türü
Elektronik
Erişim Linki
Makaleye Git
Alan
Sağlık Bilimleri Temel Alanı-
İç Hastalıkları
YÖKSİS Yazar Kaydı
Yazar Adı
,ÇETİN MUSTAFA,ZARARSIZ GÖKMEN,HÜLYA ŞIVGIN,KURNAZ FATİH,KAYNAR LEYLAGÜL,KEKLİK MUZAFFER,ÖZENMİŞ TAHSİN,BALDANE SÜLEYMAN,ESER BÜLENT,ÜNAL ALİŞIVGIN SERDAR
YÖKSİS ID
802495
Hızlı Erişim
Metrikler
Scopus Atıf
14
Yazar Sayısı
11